Treating CME with new gen NSAID

Article

Treatment of cystoid macular edema with the new-generation NSAID nepafenac 0.1%

Treatment of cystoid macular edema with the new-generation NSAID nepafenac 0.1%, from the January 2009 issue of Clinical Ophthalmology.

Please click here to read the full article.

Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Sunita Radhakrishnan, MD, an associate at the Glaucoma Center of San Francisco, speaks at the annual Glaucoma 360 meeting about electrical neurostimulation.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content
Wooden blocks which say PHASE and a block at the end with the numbers 1/2. The last block is switching from 1 to 2. This represents a clinical trial moving through phases. Image credit: ©rabbitti – stock.adobe.com

First patient dosed in Phase 1/2 ASTRA study for Stargardt disease therapy SB-007 (SpliceBio)

Hattie Hayes
March 13th 2025
Article

SpliceBio continues to actively enroll patients in the ASTRA study and accompanying POLARIS trial

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

Left to Right – Back Row: Peter Holland, CEO, IAPB, H.E. Gladys Mokhawa, Permanent Representative of Botswana to the United Nations, H.E Ambassador Walton Webson, Permanent Representative of Antigua and Barbuda to the United Nations &             Co-Chair and Founder of the UN Friends of Vision Group, Dr. A.H. Monjurul Kabir, Global Adviser and Team Leader, Gender Equality and Disability Inclusion, Mr. Werner Obermeyer, Director WHO, New York Front Row: Jennifer Gersbeck, Executive Director – Influence and Scaling Impact at The Fred Hollows Foundation and Co-Chair of the IAPB Gender Equity Work Group, HRH The Duchess of Edinburgh, Ms Tara Soomro, Permanent Mission of United Kingdom to the United Nations & Ambassador ECOSOC Affairs . Image courtesy of the International Agency for the Prevention of Blindness.

Her Royal Highness The Duchess of Edinburgh delivers keynote address on gender equity in eye care

Hattie Hayes
March 12th 2025
Article

The UN Friends of Vision group meeting coincided with International Women's Day and the UN Commission on the Status of Women

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

A black-and-white image of a woman placing her hand over her eye, as if in pain. A red glow on her eye area indicates she is experiencing neuropathic corneal pain. Image credit: ©mykolasamoilenk – stock.adobe.com

OKYO Pharma files US FDA Fast Track application for neuropathic corneal pain treatment urcosimod

Martin David Harp
March 11th 2025
Article

Urcosimod, formerly known as OK-101, showed clear statistical significance in multiple endpoints in a recently completed Phase 2 trial

A close-up of an eyeball looking at the tip of a syringe needle. There is a droplet of liquid coming from the syringe. Concept image for anti-VEGF and diabetic macular oedema. Image credit: ©kikkerdirk – stock.adobe.com

Renal dysfunction negatively impacts effect of diabetic macular oedema therapy

Lynda Charters
March 11th 2025
Article

Additionally, the prognosis of macular oedema may help clinicians evaluate renal function, investigators reported

© 2025 MJH Life Sciences

All rights reserved.